A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s immune system to produce defence proteins, which are then transferred to the foetus through the placenta. This maternal immunity offers newborns with instant defence from the point of delivery, precisely when they are most vulnerable to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst noting that protection remains possible even if administered later in the third trimester.
- Nearly 85 per cent protection when vaccinated 4 weeks before birth
- Antibodies from the mother passed through the placenta protect newborns from day one
- Coverage possible with 2-week gap before early delivery
- Vaccination in third trimester still provides significant infant protection
Strong evidence from recent research
The efficacy of the pregnancy RSV vaccine has been confirmed through a thorough investigation undertaken in England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month period, providing comprehensive and reliable data of the vaccine’s real-world impact. The study’s conclusions have been validated by the UK Health Security Agency as showing robust protection for newborns during their most vulnerable early months. The scope of this study provides healthcare professionals and parents-to-be with confidence in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.
The results paint a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV during the study period, with the great majority being infants whose mothers had not received the vaccination. This clear distinction emphasises the vaccine’s critical role in protecting against serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a significant public health achievement, potentially preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings reinforce the importance of the vaccination programme introduced in the UK in 2024.
Research approach and coverage
The research analysed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospitalisations. The substantial sample size and comprehensive nature of the data collection ensured that findings were statistically significant and representative of the broader population, rather than individual cases or limited subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology measured real-world outcomes rather than laboratory-based settings, providing real-world data of how the vaccine functions when given across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and its hazards
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.
The infection produces inflammation deep within the lungs and airways, making it dangerously difficult for affected infants to feed and breathe adequately. Parents frequently observe their babies visibly struggling, their chests rising whilst they attempt to draw adequate oxygen into their compromised lungs. Whilst the majority of babies improve through palliative treatment, a modest yet notable group succumb from RSV-related complications yearly, making immunisation programmes a critical public health imperative for defending the youngest and most vulnerable members of society.
- RSV produces inflammation in lungs, leading to severe breathing difficulties in babies
- Nearly 50% of infants contract the infection during their first few months alive
- Symptoms range from minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
- Over 20,000 UK infants need serious hospital treatment for RSV each year
- Small numbers of infants die from RSV related complications each year in the UK
Adoption rates and specialist advice
Since the RSV vaccine programme began in 2024, health officials have highlighted the value of pregnant women receiving their jab at the ideal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing matters greatly for ensuring newborns benefit from the maximum immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery provides nearly 85% protection, experts recommend women to receive their vaccine as early as possible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies via the placenta.
The communication from public health bodies stays clear: pregnant women ought to prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has reassured pregnant women that protection remains still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This flexible approach acknowledges the practical demands of pregnancy whilst ensuring strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.
Regional disparities in immunisation
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Certain regions have attained greater immunisation rates among qualifying expectant mothers, whilst others remain focused to boost understanding and access to the jab. These regional differences demonstrate differences across medical facilities, engagement approaches, and local engagement efforts, though the national data demonstrates consistently strong protection irrespective of geographical location.
- NHS trusts launching diverse outreach initiatives to connect with pregnant women
- Geographic variations in immunisation take-up in different parts of England require targeted improvement
- Regional health providers modifying schemes to suit local requirements and situations
Real-world impact and parental perspectives
The vaccine’s impressive effectiveness delivers concrete gains for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV before the introduction of this preventative solution, the 80% decrease in admissions means thousands of infants shielded from serious illness. Parents no more face the upsetting situation of watching their newborns gasping for air or struggle to eat, symptoms that mark critical RSV illness. The vaccine has substantially transformed the landscape of neonatal respiratory health, providing expectant mothers a proactive tool to safeguard their most vulnerable children during those critical early months.
For families like that of Malachi, whose serious RSV infection caused devastating brain damage, the vaccine’s availability carries significant emotional significance. His mother’s advocacy for the jab emphasises the transformative consequences that treatable infection can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story strikes a chord with parents now provided with protection. The knowledge that such significant complications—hospital stay, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to expectant mothers during their late pregnancy, changing what was once an predictable seasonal threat into a manageable risk.